Genocea Biosciences (NASDAQ:GNCA) & NKGen Biotech (NYSE:NKGN) Head-To-Head Contrast
by Kim Johansen · The Markets DailyProfitability
This table compares Genocea Biosciences and NKGen Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
| NKGen Biotech | N/A | N/A | -479.36% |
Volatility and Risk
Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
Insider & Institutional Ownership
0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Genocea Biosciences and NKGen Biotech”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genocea Biosciences | $1.91 million | 0.00 | -$33.20 million | ($0.61) | N/A |
| NKGen Biotech | N/A | N/A | -$82.94 million | ($1.72) | -0.02 |
Genocea Biosciences has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Genocea Biosciences beats NKGen Biotech on 6 of the 9 factors compared between the two stocks.
About Genocea Biosciences
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
About NKGen Biotech
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.